Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04661852
Title	Cabozantinib With Topotecan-Cyclophosphamide
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Dana-Farber Cancer Institute
Indications	osteosarcoma neuroectodermal tumor Ewing sarcoma
Therapies	Cabozantinib + Cyclophosphamide + Pegfilgrastim + Topotecan Cabozantinib + Cyclophosphamide + Filgrastim + Topotecan
Age Groups:	adult \| child
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Boston Children's Hospital		Boston	Massachusetts	02115	United States	Details
Dana-Farber Cancer Institute		Boston	Massachusetts	02115	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field